BridgeBio Pharma, Inc. — Director's Dealing 2024

Nov 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-11-19

Reporting Person: STEPHENSON BRIAN C (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-19	Common Stock	S	4156	$22.4102	Disposed	93758	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F2: Represents the weighted average sale price of the shares sold ranging from $21.95 to $22.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.